First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market
First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market
First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 366,000 shares of the Company's common stock (or common stock equivalents) at a price of $2.95 per share in a registered direct offering priced at-the-market under Nasdaq rules.
First Wave BioPharma, Inc.（納斯達克股票代碼：FWBI）（“First Wave BioPharma” 或 “公司”）是一家臨床階段的生物製藥公司，專門開發胃腸道（GI）的靶向非系統性療法，今天宣佈，它已與某家機構投資者簽訂了最終證券購買協議，以購買和出售該公司36.6萬股普通股（或根據納斯達克規則，在市場上定價的註冊直接發行中，普通股等價物），每股價格爲2.95美元。
In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 732,000 shares of common stock. The warrants have an exercise price of $2.70 per share, will be exercisable immediately following the date of issuance and will have a term of six years following the date of issuance.
此外，在同時進行的私募中，公司將向投資者發行認股權證，購買最多732,000股普通股。認股權證的行使價爲每股2.70美元，將在發行之日後立即行使，自發行之日起有效期爲六年。
Roth Capital Partners is acting as the exclusive placement agent for the offering.
羅斯資本合夥人是此次發行的獨家配售代理。